$HIMS

FTC Sues Hims & Hers Over Health Data, Subscription Claims

The FTC, Utah, and Los Angeles County sued Hims & Hers Health Inc., alleging the telehealth provider shared patients’ sensitive health data with ad platforms such as Meta and Snap while claiming privacy protections. Regulators also allege deceptive billing and subscription practices, including charges after intake forms and unclear cancellation timing. The case is pending in federal court.

Original reporting
Published Aug 4, 2026, 3:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FTC Sues Hims & Hers Over Health Data, Subscription Claims — source image
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

If the court grants relief, HIMS could face injunctions affecting ad-tech data sharing, required disclosures around intake-to-charge timing, and changes to subscription cancellation mechanics. Even without an immediate ruling, the filing can pressure sentiment and increase compliance spend.

02

Market read

This is a fresh US regulatory enforcement filing targeting HIMS’ privacy disclosures and subscription billing practices, creating immediate legal and compliance headline risk.

03

What to watch

Potential settlement or consent decree terms, the scope of alleged affected customers, and whether the case triggers immediate operational changes (tracking, billing, cancellation UX) that could offset legal risk.

Relevance 8/10Novelty 8/10Timing: today, after-hours legal filing headline risk

Background

The FTC voted 2-0 to authorize the complaint, alleging violations of the FTC Act and the Restore Online Shoppers’ Confidence Act, alongside state false-advertising and consumer sales practices claims.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

FTC and Utah and Los Angeles County sued Hims & Hers, alleging it shared sensitive health data with ad platforms and used deceptive subscription billing.

Expected impact

Near-term downside bias on enforcement headlines and legal-cost expectations; magnitude depends on court outcomes and any settlement terms.

Evidence & confidence

The article describes a newly filed federal lawsuit alleging privacy violations and deceptive billing, which can drive immediate risk repricing even before adjudication.

Market effects

Telehealth and DTC subscription providers face heightened scrutiny over privacy disclosures, tracking, and cancellation flows.

US enforcement actions by FTC and state/local regulators increase compliance uncertainty for operators serving these jurisdictions.

Moderate, as privacy and subscription enforcement themes can influence cross-border regulatory expectations for digital health.

Counterpoint

HIMS may argue the allegations are unproven and that its actual consent and consultation workflows differ from the complaint’s characterization, limiting downside if courts dismiss or narrow claims.

Key entities

  • Hims & Hers Health Inc.

    Telehealth provider sued by the FTC, Utah, and Los Angeles County over alleged health-data sharing and deceptive subscription billing/cancellation practices.

  • Federal Trade Commission (FTC)

    Authorized and filed the federal complaint alleging privacy and recurring-charge/cancellation violations.

  • Meta Platforms Inc.

    Allegedly received customer information from Hims & Hers via advertising platforms, per the complaint.

  • Snap Inc.

    Allegedly received customer information from Hims & Hers via advertising platforms, per the complaint.

  • Utah

    Alleged violations of its Consumer Sales Practices Act.

Related articles

$HIMSHighAI 9/10

FTC Sues Hims & Hers Over Health Privacy and Billing Practices

The U.S. FTC sued telehealth company Hims & Hers, joined by California and Utah, alleging it shared consumers’ private health data with ad platforms owned by Meta and Snap and billed some customers for prescriptions without meaningful consultation. The FTC also alleges unclear refill and subscription cancellation practices. Hims said its privacy policy lets patients choose data use; its stock fell nearly 12% on Wednesday.

$HIMSMed

‘They Are Thieves’: FTC Complaints About Hims & Hers Detail Surprise Charges

The FTC filed a lawsuit against telehealth company Hims & Hers (Hims & Hers Health, Inc.) alleging it disclosed private health information to third parties and used subscription practices consumers say were misleading. According to the FTC, there were over 4,800 complaints in five years. Complaints cited surprise subscription charges, refund denials, limited medical support, and hard-to-reach support.

$HIMSMedAI 8/10

As GLP-1s Transform Telehealth, the FTC Takes Aim at Hims

The FTC, according to its July 29 complaint, is suing Hims & Hers Health over alleged deceptive practices in telehealth subscription enrollment and privacy. The FTC claims consumers were charged for automatically renewing prescription subscriptions without informed consent, faced unclear refill timing and difficult cancellation, and were misled about how sensitive data was handled. The FTC seeks injunctions and monetary remedies.

$HIMSMed

HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform

Hims & Hers Health (HIMS) said it added eight partners to its Hims & Hers Benefits program, covering fitness, nutrition, preventive health and glucose monitoring. It integrated Dexcom’s Stelo with discounts passed to subscribers. HIMS shares rose about 1% and analysts at BofA cut its price target to $25. For 2026, Hims forecasts $2.8B to $3.0B revenue and $275M to $350M EBITDA.

$HIMSMed

Hinge Health, Inc. Q2 2026 Earnings Call Summary

Hinge Health reported Q2 2026 revenue up 53% year over year, citing higher yield from targeted enrollment and referrals. Operating margin rose 1,000 bps to 29%. Full-year 2026 revenue guidance increased to $856 million-$860 million. Hinge plans to expand beyond MSK via a $105 million acquisition of Cylinder Health, expected to add $7 million-$8 million in 2026 revenue and lift margins over 1-2 years.

$HIMSMed

HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Kirby McInerney LLP said it is investigating potential securities-fraud claims against Hims & Hers Health, Inc. (NYSE: HIMS). The probe follows an FTC lawsuit filed July 29, 2026 alleging Hims shared customers’ medical information with third-party advertisers, including Meta Platforms. After the news, Hims shares fell $4.32, or 14.73%, to $25.00.